| human | Q5 |
| P496 | ORCID iD | 0000-0002-3271-5356 |
| P1053 | ResearcherID | R-5212-2016 |
| P2038 | ResearchGate profile ID | Silje-Nord |
| P27 | country of citizenship | Norway | Q20 |
| P108 | employer | Oslo University Hospital | Q3111191 |
| P734 | family name | Nordgard | Q122837817 |
| Nordgard | Q122837817 | ||
| Nordgard | Q122837817 | ||
| P735 | given name | Silje | Q14437806 |
| Silje | Q14437806 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
| Q35870483 | A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients |
| Q57421083 | ABCB1 and GST polymorphisms associated with TP53 status in breast cancer |
| Q44747337 | ABI3 mediates expression of the peroxiredoxin antioxidant AtPER1 gene and induction by oxidative stress |
| Q34165640 | Allele-specific copy number analysis of tumors |
| Q44118153 | Analyzing cancer samples with SNP arrays |
| Q35218520 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy |
| Q36178189 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. |
| Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
| Q60044516 | Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors |
| Q61443309 | Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors |
| Q36070080 | Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival |
| Q58792549 | Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4 |
| Q64067663 | Breast cancer quantitative proteome and proteogenomic landscape |
| Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
| Q35587062 | Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN |
| Q43591112 | Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors |
| Q34566212 | Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft |
| Q81535508 | ESR1 gene amplification in breast cancer: a common phenomenon? |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
| Q37236216 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
| Q36248936 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q36465244 | Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes |
| Q34595718 | Genetic variation in putative regulatory loci controlling gene expression in breast cancer |
| Q53485693 | Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients. |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q39042751 | Glycan-related gene expression signatures in breast cancer subtypes; relation to survival |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q36014067 | Identification of novel genetic markers of breast cancer survival |
| Q35779345 | Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling |
| Q41890841 | Integrated study of copy number states and genotype calls using high-density SNP arrays |
| Q37728699 | Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome |
| Q47418015 | Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials |
| Q34158058 | Large-scale genotyping identifies a new locus at 22q13.2 associated with female breast size |
| Q38503758 | Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer |
| Q37421423 | Next-generation sequencing of disseminated tumor cells |
| Q28388563 | Overrepresentation of transcription factor families in the genesets underlying breast cancer subtypes |
| Q45988269 | Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors. |
| Q27863385 | Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. |
| Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q54342687 | Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer. |
| Q44606652 | Seed 1-cysteine peroxiredoxin antioxidants are not involved in dormancy, but contribute to inhibition of germination during stress |
| Q54544869 | Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients. |
| Q37661498 | The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors |
| Q39527587 | The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma |
| Q47852784 | The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer |
| Q93012400 | The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers |
| Q51779053 | The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer. |
| Q59800663 | Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations |
| Q28396153 | Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing |
| Q36559648 | Transcriptional networks inferred from molecular signatures of breast cancer |
Search more.